Leerink Partnrs Has Bearish Forecast for EW Q4 Earnings

Key Points

• Analysts at Leerink Partners have revised their Q4 2025 earnings per share estimate for Edwards Lifesciences from $0.63 to $0.57, reflecting a bearish outlook.
• The company reported a quarterly EPS of $0.67, surpassing the consensus estimate of $0.62, with revenues of $1.53 billion, an 11.9% year-over-year increase.
• Despite the positive quarterly results, several analysts maintain hold and buy ratings, with a consensus price target of $85.00 for the stock.

Edwards Lifesciences Corporation (NYSE:EW - Free Report) - Equities researchers at Leerink Partnrs cut their Q4 2025 earnings estimates for Edwards Lifesciences in a report released on Friday, July 25th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will earn $0.57 per share for the quarter, down from their previous forecast of $0.63. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2026 earnings at $2.80 EPS, FY2027 earnings at $3.28 EPS, FY2028 earnings at $3.75 EPS and FY2029 earnings at $4.24 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.25%. The business's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.70 EPS.

Several other research analysts also recently weighed in on EW. Deutsche Bank Aktiengesellschaft boosted their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a "buy" rating in a research note on Friday. Mizuho increased their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday. Barclays lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday. Truist Financial increased their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday. Finally, Stifel Nicolaus increased their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $85.00.

Edwards Lifesciences Price Performance

Shares of NYSE:EW traded down $1.54 during midday trading on Monday, reaching $78.46. 6,024,534 shares of the company were exchanged, compared to its average volume of 4,283,557. The business's fifty day moving average is $76.58 and its two-hundred day moving average is $73.55. Edwards Lifesciences has a one year low of $59.41 and a one year high of $83.00. The stock has a market cap of $46.02 billion, a PE ratio of 11.29, a price-to-earnings-growth ratio of 4.00 and a beta of 1.11. The company has a current ratio of 4.45, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the company. Prosperity Consulting Group LLC grew its holdings in Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock valued at $289,000 after buying an additional 134 shares in the last quarter. Arlington Trust Co LLC raised its holdings in shares of Edwards Lifesciences by 1.2% during the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after acquiring an additional 135 shares during the period. Valeo Financial Advisors LLC grew its holdings in shares of Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after purchasing an additional 142 shares during the period. Versant Capital Management Inc grew its holdings in shares of Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after purchasing an additional 145 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock worth $2,170,000 after purchasing an additional 145 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the sale, the chief financial officer owned 41,098 shares in the company, valued at approximately $3,057,691.20. This trade represents a 21.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,962 shares of company stock valued at $2,641,387 in the last three months. 0.34% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.